jargon-translator — independently scanned and version-tracked by SaferSkills.
SaferSkills independently audited jargon-translator (Agent Skill) and scored it 100/100 (green). The audit ran 55 deterministic rules across Security, Supply Chain, Maintenance, Transparency, and Community; it found 0 high-severity and 0 lower-severity findings. The full rule-by-rule trace and per-finding evidence are below. Free, methodology-open.
Findings & checks · 0 flagged
Every scanned point with the score it earned and what moved between them.
First recorded scan — no prior version to compare against.
The primary manifest — the file an agent reads to learn what this artifact does.
Rewrites scientific, legal, financial, or technical jargon into plain language suitable for a general news audience — preserving accuracy while making the meaning immediately clear to a non-specialist reader.
Required: The jargon-heavy text you want translated — a passage, sentence, or list of terms. Specify the field the jargon comes from if it is not obvious (medical, legal, financial, scientific, technological, military, bureaucratic).
Optional: The target audience (general reader, semi-specialist, young adult); the publication context (news article, broadcast script, social media post — each has different register requirements); specific terms you find most confusing; whether you want term-by-term translations, a full rewrite, or both.
Three components delivered in sequence: Glossary (a table or list of jargon terms with plain-language equivalents), Full Rewrite (the complete passage in plain language), and One-Sentence Summary (the core meaning in a single sentence). Any trade-offs between simplicity and precision are noted in brackets within the rewrite. Tone: conversational, clear, accurate. Length depends on the input — the rewrite should be roughly the same length as the original or shorter, never significantly longer.
Text: "The phase III randomised, double-blind, placebo-controlled trial demonstrated non-inferiority of the novel therapeutic agent relative to the standard-of-care comparator on the primary endpoint of progression-free survival (HR 0.87, 95% CI 0.74–1.02, p=0.09), with a clinically meaningful improvement in the secondary endpoint of objective response rate (42% vs. 31%, p=0.003)."
Field: Medical / clinical trials Audience: General newspaper reader Need: Glossary, full rewrite, and one-sentence summary
Glossary
| Term | Plain-Language Equivalent |
|---|---|
| Phase III trial | The final and largest stage of testing a new treatment before it can be approved for general use |
| Randomised | Patients were assigned to treatment groups by chance (like a coin flip) to ensure a fair comparison |
| Double-blind | Neither the patients nor the doctors knew who was getting the real treatment and who was getting the dummy pill |
| Placebo-controlled | One group received a dummy treatment (placebo) to compare against the real treatment |
| Non-inferiority | The study was designed to show the new treatment is at least as good as the existing treatment — not necessarily better |
| Novel therapeutic agent | The new drug being tested |
| Standard-of-care comparator | The existing treatment that patients currently receive |
| Primary endpoint | The main outcome the study was designed to measure |
| Progression-free survival | How long patients lived without their disease getting worse |
| HR 0.87 | Hazard ratio — a measure of relative risk. 0.87 means patients on the new drug had a 13% lower rate of disease progression, but... |
| 95% CI 0.74–1.02 | ...the confidence interval crosses 1.0, meaning the result could be due to chance |
| p=0.09 | The statistical test for the main outcome did not reach the conventional threshold for significance (p<0.05) — the result is suggestive but not conclusive |
| Secondary endpoint | A supporting outcome the study also measured, but not the main one |
| Objective response rate | The percentage of patients whose tumours shrank measurably |
Full Rewrite
In the final stage of testing, the new drug was compared to the current standard treatment in a rigorously designed trial involving [number not specified] patients. Neither the patients nor their doctors knew who received which treatment, and patients were assigned to groups at random.
On the study's main measure — how long patients lived without their disease worsening — the new drug performed similarly to the existing treatment. Patients on the new drug had a 13% lower rate of disease progression, but this result did not reach statistical significance [meaning it could be due to chance rather than a real difference].
On a secondary measure — the percentage of patients whose tumours shrank — the new drug showed a clearer advantage: 42% of patients responded to the new drug compared to 31% on the existing treatment. This difference was statistically significant.
[Trade-off note: The original text describes the primary result as "non-inferiority," which has a specific statistical meaning — the study was designed to show the new drug is "not worse" rather than "better." This is a meaningful distinction in regulatory terms: a drug that meets non-inferiority standards may be approved even without proving superiority, particularly if it has other advantages such as fewer side effects or easier administration. The plain-language version simplifies this to "performed similarly," which is accurate for a general audience but loses the regulatory nuance.]
One-Sentence Summary
A large clinical trial found that a new drug was roughly as effective as the current treatment at slowing disease progression, and may be better at shrinking tumours, but the main result was not statistically conclusive.
~30 seconds. Free. No account. Every finding cites a rule and a line of evidence.